Article
Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies.
The hematology journal : the official journal of the European Haematology Association - 1 Jan 2004
Pelizzari Anna Maria, Motta Maddalena, Cariani Elisabetta, Turconi Paola, Borlenghi Erika, Rossi Giuseppe
Abstract excerpt
Hepatitis B virus (HBV) reactivation is a potentially fatal complication of chemotherapy in asymptomatic HBV carriers. Prophylactic lamivudine has proven effective for its prevention, but the potential emergence of lamivudine-resistant HBV YMMD mutants, as shown in patients treated for chronic hepatitis, may limit its use. To evaluate the frequency of HBV YMMD mutant and its clinical significance, we have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
